ANCHORAGE, Alaska, Jan. 20, 2026 /CNW/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") is pleased to announce the ...

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

Federal Reserve policymakers were deeply divided over the decision to cut interest rates at their meeting in December as the U.S. economy faces a challenging combination of risks, according to the ...

The West Virginia Mountaineers looked absolutely dominant on Sunday as they crushed Houston in the opening match-up of their Big 12 schedule, running away to 101-46 victory at the Hope Coliseum in ...

Brian Smith was fired as Ohio University's head football coach for multiple violations of his contract, including an extramarital affair with an undergraduate student, according to records obtained ...

For the second time in the span of 12 months, Rutgers is looking for a new defensive coordinator. Defensive coordinator Robb Smith was fired following the first year of his third stint with the ...

Wednesday night was a historic performance all around for the No. 10 Iowa State Cyclones in a 132-68 rout over Alcorn State. A win over the 1-9 Braves from the SWAC would not typically generate a lot ...

CINCINNATI — Brendan Sorsby is already getting serious offers from other football programs, according to the latest report from CBS Sports analyst Rick Neuheisel. He noted on his CBS Sports Radio show ...

A pair of educators at Boylston Elementary School were arrested last week and charged with assaulting multiple children on Nov. 21 at an after-school program, according to a police report. Benjamin ...

The Second City New York will expand its holiday programming this season with a range of improv productions scheduled throughout December. The lineup will include family-friendly weekend performances ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS). RRMS ...